Live tape
Top 8, mentions 7d14,333GOOGL2,869 mentions▲ +0.04NVDA2,215 mentions▲ +0.05AMD1,940 mentions▲ +0.08QQQ1,751 mentions▲ +0.05AAPL1,729 mentions▲ +0.05SPY1,560 mentions▲ +0.06TSLA1,164 mentions▲ +0.06SPCX1,105 mentions▲ +0.05

Equity · Healthcare

NAMS

NASDAQ

NewAmsterdam Pharma Co (NAMS)

31.67 USD +2.13% vs prior close
NewAmsterdam Pharma Company N.V. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for NAMS to draw a line in its place.

Track this symbol on TradingView
Market cap
3.8B USD
Revenue, year to Dec 2025
22.5M USD
EPS, diluted, year to Dec 2025
−1.72 USD
52-week range
21 USD – 41 USD
Avg volume
263.6K

as of Jul 17, 2026

Have NewAmsterdam Pharma Co (NAMS) insiders bought or sold shares recently?

In the 90 days to 9 Nov 2026, NewAmsterdam Pharma Co insiders reported 3 open-market sales and 1 purchase (SEC Form 4).

Form 4, 90 days to 9 Nov 2026, newest reported trade 30 Sep 2026

Buys 1Sells 3Net sold $4.44MOther filings 3

Have NewAmsterdam Pharma Co (NAMS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
30 Sep 2026Kastelein Johannes Jacob PieterChief Scientific OfficerSell50,2461.3M USD
14 Sep 2026Davidson Michael H.Chief Executive OfficerBuy10,000227K USD
04 Sep 2026Smither John WDirectorSell1,60041K USD
24 Aug 2026Kastelein Johannes Jacob PieterChief Scientific OfficerSell125,0003.4M USD
Bought1 open-market purchase10,000$227K
Sold3 open-market sales176,846$4.66M
3 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have NewAmsterdam Pharma Co (NAMS) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
30 Sep 2026Kastelein Johannes Jacob PieterChief Scientific OfficerOption exercise50,246
01 Sep 2026Gunning Robert WilliamVice President, ControllerAward3,200
24 Aug 2026Kastelein Johannes Jacob PieterChief Scientific OfficerOption exercise125,000

Which funds hold NewAmsterdam Pharma Co (NAMS)?

11 of the 45 institutional funds we track reported a NewAmsterdam Pharma Co position for the quarter ended 30 Jun 2026 — a combined 412.6M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold NewAmsterdam Pharma Co (NAMS)?
FundPositionSharesValueShares q/q
Viking Global InvestorsHeld (±25%)4,203,567142.5M USD
Maverick CapitalAdded3,267,802110.7M USD+49.5%
Duquesne Family OfficeHeld (±25%)3,070,146104.0M USD
Citadel AdvisorsHeld (±25%)645,80521.9M USD−9.3%
Millennium ManagementAdded501,61417.0M USD+65.1%
Point72 Asset ManagementNew position168,9015.7M USD
D. E. Shaw & Co.New position120,5614.1M USD
Man GroupNew position80,8322.7M USD
Tudor Investment CorpNew position79,4602.7M USD
AQR Capital ManagementAdded22,691769K USD+118.5%

Showing the 10 largest of 11 reported positions. The figures above count all of them.

What has been filed or recorded for NewAmsterdam Pharma Co (NAMS)?

The filings we hold for NewAmsterdam Pharma Co, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 07 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for NewAmsterdam Pharma Co (NAMS)?
And
07 Oct 2026Fails to deliverShares failed to deliver442 shares10K USD notional · <0.001% of shares out
02 Oct 2026Fails to deliverShares failed to deliver36,694 shares887K USD notional · 0.031% of shares out
01 Oct 2026Fails to deliverShares failed to deliver1,953 shares47K USD notional · 0.002% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.14 USDRevenue $19M
30 Sep 2026FinancialsTotal assets688.0M USDat period end
30 Sep 2026FinancialsTotal equity630.8M USDat period end
24 Sep 2026Fails to deliverShares failed to deliver115,916 shares2.6M USD notional · 0.097% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.52 USDRevenue $4M
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.40 USDRevenue $3M
31 Dec 2025Annual reportFY 2025 reportedEPS −1.72 USDRevenue $23M
31 Dec 2025FinancialsRevenue22.5M USDfiscal year
31 Dec 2025FinancialsNet income−203.8M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.72 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.61 USDRevenue $0M
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.15 USDRevenue $19M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.34 USDRevenue $3M
31 Dec 2024Annual reportFY 2024 reportedEPS −2.56 USDRevenue $46M

NewAmsterdam Pharma Co (NAMS): frequently asked questions

From live data
3.8B

What is NewAmsterdam Pharma Co’s market cap?

NewAmsterdam Pharma Co is worth 3.8B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

22.5M

What is NewAmsterdam Pharma Co’s revenue?

NewAmsterdam Pharma Co reported revenue of 22.5M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

3 sales

Have NewAmsterdam Pharma Co insiders bought or sold shares recently?

In the 90 days to 9 Nov 2026, NewAmsterdam Pharma Co insiders reported 3 open-market sales and 1 purchase (SEC Form 4). A further 3 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

11 of 45

Which funds own NewAmsterdam Pharma Co?

11 of the 45 funds we track reported a NewAmsterdam Pharma Co position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Viking Global Investors, Maverick Capital and Duquesne Family Office. See Funds

−0.14

When did NewAmsterdam Pharma Co last report earnings?

NewAmsterdam Pharma Co last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.14 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings